Takeda Ventures Inc, the corporate venture arm of Takeda Pharmaceutical Company, is the latest venture fund to invest in Fate Therapeutics Inc which is developing compounds that modulate stem-cell pathways. Financial details were not disclosed.
4SC AG ended the 2011 first quarter with an operating loss of €4.8 million and cash and equivalents of €5.5 million. The German small-molecule developer said it is expecting final Phase 2 data this year from three important studies.
Dendreon Corporation is seeking authorisation to open manufacturing sites at two new locations in the US for its prostate cancer vaccine, Provenge (sipuleucel-T), to meet demand for the treatment, David Urdal, CSO, told a London conference.
Sanofi Pasteur has announced US Food and Drug Administration approval of a new formulation of its Fluzone Intradermal vaccine that uses a microinjection system for intradermal delivery. Delivery is via a 90% shorter needle.
The US Food and Drug Administration has announced the approval of the first test for Staphylococcus aureus (S. aureus) infections that can quickly identify whether the bacteria are methicillin resistant (MRSA) or methicillin susceptible (MSSA).
Elan Corporation Plc said that its drug formulation and manufacturing business, Elan Drug Technologies (EDT), is to merge with Alkermes Inc to create a new company with a portfolio of 25 marketed products and annual revenue of $450 million.
Rigel Pharmaceuticals Inc announced that Pfizer Inc is returning full rights to its early clinical-stage asthma programme, R343, as a result of Pfizer’s decision to exit from the allergy and respiratory therapeutic area in research and development.
Novartis has announced US Food and Drug Administration approval of Afinitor (everolimus) for the treatment of progressive neuroendocrine tumours of pancreatic origin (NET). This is in line with a recommendation from an FDA advisory panel.
Two publicly-listed French biopharmaceutical companies, Innate Pharma SA and Transgene SA, have announced the creation of a new, joint venture company that will provide immunomonitoring services to the healthcare industry.
Clavis Pharma ASA has started recruiting patients for a Phase 3 trial of its lead product for late-stage acute myeloid leukaemia. The clinical update was issued with its first quarter results which showed cash of NOK 333 million on 31 March.